<2>Novo Nordisk’s Stock Takes a Hit After Analyst Downgrade
<3>Latest Setback for the Danish Drugmaker
<4>Novo Nordisk’s (NVO) stock has taken a hit after a sell-side analyst downgraded the stock for the first time in five years. The analyst’s decision comes after the company’s latest study showed that a new drug wasn’t as effective as a rival’s.
Bloomberg reported that the analyst, who has been following the company for years, has thrown in the towel on Novo Nordisk. The analyst’s downgrade is a significant blow to the company, which has been struggling to regain momentum in recent years.
<5>The analyst’s decision to downgrade Novo Nordisk’s stock is based on the company’s latest study, which showed that a new drug was not as effective as a rival’s. The study, which was published in a peer-reviewed journal, compared the efficacy of Novo Nordisk’s new drug to a rival’s drug.